Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
Open accessThe DOI matches its Crossref record; 152 of the 154 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To formulate clinical practice guidelines for the pharmacological management of obesity. PARTICIPANTS: An Endocrine Society-appointed Task Force of experts, a methodologist, and a medical writer. This guideline was co-sponsored by the European Society of Endocrinology and The Obesity Society. EVIDENCE: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe the strength of recommendations and the quality of evidence. CONSENSUS PROCESS: One group meeting, several conference calls, and e-mail communications enabled consensus. Committees and members of the Endocrine Society, the European Society of Endocrinology, and The Obesity Society reviewed and commented on preliminary drafts of these guidelines. Two systematic reviews were conducted to summarize some of the supporting evidence. CONCLUSIONS: Weight loss is a pathway to health improvement for patients with obesity-associated risk factors and comorbidities. Medications approved for chronic weight management can be useful adjuncts to lifestyle change for patients who have been unsuccessful with diet and exercise alone. Many medications commonly prescribed for diabetes, depression, and other chronic diseases have weight effects, either to promote weight gain or produce weight loss. Knowledgeable prescribing of medications, choosing whenever possible those with favorable weight profiles, can aid in the prevention and management of obesity and thus improve health.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“In contrast, the National Institute for Health and Clinical Excellence (NICE) [37], Endocrine Society [35], and American College of Cardiology [36] uniformly recommend using only licensed medications for weight management and did not consider off-label options such as metformin.”
From A systematic review of licensed weight-loss medications in treating antipsychotic-induced weight gain and obesity in schizophrenia and psychosis. (2022) · cites this paper as [35]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The STEP 1, 3, and 4 trials used semaglutide in conjunction with a lifestyle program and resulted in 16.9% to 18.2% weight-loss (using a completers-type analysis), which is superior to phase 3 trial results for other weight-loss medications, though without head-to-head drug comparison.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [759]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Commonly prescribed medications such as antidepressants (eg, mirtazapine, amitriptyline) and antihyperglycemics such as glyburide or insulin cause weight gain, and clinicians should review and consider alternatives.”
From Obesity Management in Adults: A Review (2023) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consideration of individual food preferences, cultural traditions, and budgetary requirements may aid in the adherence to healthy dietary patterns, a key predictor of success [42,45].”
From Nutritional considerations with antiobesity medications (2024) · cites this paper as [42]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Medication classes promoting weight gain include antihyperglycemics (eg, glyburide, insulin), antidepressants (eg, amitriptyline, mirtazapine), antipsychotics (eg, olanzapine, quetiapine), antiepileptics (eg, gabapentin, carbamazepine), β-blockers, progesterone-based contraceptives, corticosteroids, and antiretroviral therapy (eg, protease inhibitors).12,77”
From Obesity Management in Adults: A Review (2023) · cites this paper as [12]
Experimental — accuracy not yet measured
29 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873 · cited 1×
“The AHA/ ACC/TOS Guideline for the Management of Overweight and Obesity in Adults reviewed randomized clinical trials on weight loss interventions and determined that the best weight loss outcomes occur with frequent face-to-face visits (16 visits per year on average) (8, 38).”
BackgroundGrading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“The Task Force followed the approach recommended by the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) group, an international group with expertise in the development and implementation of evidence-based guidelines (1).”
MethodOverweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults
Calle, E. E., Rodriguez, C., Walker-Thurmond, K., & Thun, M. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021423 · Cited by 7,696 · cited 1×
“obese are at increased risk for many malignancies (7).”
BackgroundDecision aids for people facing health treatment or screening decisions
Stacey, D., Légaré, F., Lewis, K., Barry, M. J., Bennett, C. L., Eden, K. B., Holmes-Rovner, M., Llewellyn-Thomas, H., Lyddiatt, A., Thomson, R., et al. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001431.pub5 · Cited by 6,685
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.004 · Cited by 4,058
Self-citationNathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Weight and Type 2 Diabetes after Bariatric Surgery: Systematic Review and Meta-analysis
Buchwald, H., Estok, R., Fahrbach, K., Banel, D., Jensen, M. D., Pories, W. J., Bantle, J. P., & Sledge, I. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.09.041 · Cited by 2,551 · cited 1×
“T2DM Yes Cohen, 2012 (132); Mingrone, 2012 (133); Schauer, 2012 (134); Buchwald, 2009 (135) Hypertension Yes Ilane-Parikka, 2008 (136); Phelan, 2007 (137); Zanella, 2006 (138) Dyslipidemia and metabolic syndrome Yes Ilane-Parikka, 2008 (136); Phelan, 2007 (137); Zanella, 2006 (138) Cardiovascular disease Yes Wannameth…”
Central nervous system control of food intake and body weight
Morton, G. J., Cummings, D. E., Baskin, D. G., Barsh, G. S., & Schwartz, M. W. (2006) · Nature · doi:10.1038/nature05026 · Cited by 2,503 · cited 1×
“GLP-1 agonists also affect the POMC neurons and cause satiety (18).”
BackgroundBariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes
Schauer, P. R., Kashyap, S. R., Wolski, K., Brethauer, S. A., Kirwan, J. P., Pothier, C. E., Thomas, S., Abood, B., Nissen, S. E., & Bhatt, D. L. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200225 · Cited by 2,164
XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study
Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.155 · Cited by 1,915 · cited 1×
“Orlistat blocks absorption of 25 to 30% of fat calories and is not appreciably absorbed systemically (28, 29).”
BackgroundBariatric Surgery versus Conventional Medical Therapy for Type 2 Diabetes
Mingrone, G., Panunzi, S., De Gaetano, A., Guidone, C., Iaconelli, A., Leccesi, L., Nanni, G., Pomp, A., Castagneto, M., Ghirlanda, G., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200111 · Cited by 1,791
Anatomy and regulation of the central melanocortin system
Cone, R. D. (2005) · Nature Neuroscience · doi:10.1038/nn1455 · Cited by 1,583
Long-term persistence of hormonal adaptations to weight loss
Sumithran, P., Prendergast, L. A., Delbridge, E., Purcell, K., Shulkes, A., Kriketos, A., & Proietto, J. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105816 · Cited by 1,449 · cited 1×
“sisting food cues or by reducing caloric absorption (14).”
BackgroundEffect of weight loss with lifestyle intervention on risk of diabetes
Hamman, R. F., Wing, R. R., Edelstein, S. L., Lachin, J. M., Bray, G. A., Delahanty, L., Hoskin, M., Kriska, A. M., Mayer-Davis, E. J., Pi-Sunyer, X., et al. (2006) · Diabetes Care · doi:10.2337/dc06-0560 · Cited by 1,344
Sjöström, L., Rissanen, A., Andersen, T., Boldrin, M., Golay, A., Koppeschaar, H. P., & Krempf, M. (1998) · The Lancet · doi:10.1016/s0140-6736(97)11509-4 · Cited by 1,237
Wing, L. M. H., Reid, C. M., Ryan, P., Beilin, L. J., Brown, M. A., Jennings, G. L. R., Johnston, C. I., McNeil, J. J., Macdonald, G. J., Marley, J. E., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021716 · Cited by 1,130 · cited 2×
“ported slightly better cardiovascular outcomes in hypertensive men treated with a regimen that began with an ACE inhibitor compared with a regimen starting with a diuretic (95).”
BackgroundMessier, S. P., Loeser, R. F., Miller, G. D., Morgan, T. M., Rejeski, W. J., Sevick, M. A., Ettinger, W. H., Pahor, M., & Williamson, J. D. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20256 · Cited by 1,065 · cited 1×
“T2DM Yes Cohen, 2012 (132); Mingrone, 2012 (133); Schauer, 2012 (134); Buchwald, 2009 (135) Hypertension Yes Ilane-Parikka, 2008 (136); Phelan, 2007 (137); Zanella, 2006 (138) Dyslipidemia and metabolic syndrome Yes Ilane-Parikka, 2008 (136); Phelan, 2007 (137); Zanella, 2006 (138) Cardiovascular disease Yes Wannameth…”
Gadde, K. M., Allison, D. B., Ryan, D. H., Peterson, C. A., Troupin, B., Schwiers, M. L., & Day, W. W. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60205-5 · Cited by 1,064 · cited 1×
“The product label recommends a gradual reduction of dose over 3–5 days because of the observation of seizures occurring when topiramate was stopped abruptly in patients with epilepsy (41, 43, 61).”
BackgroundSelf-citationGarber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057
Avenell, A., Broom, J., Brown, T., Poobalan, A., Aucott, L., Stearns, S., Smith, W., Jung, R., Campbell, M., & Grant, A. (2004) · Health Technology Assessment · doi:10.3310/hta8210 · Cited by 1,041
Greenway, F. L., Fujioka, K., Plodkowski, R. A., Mudaliar, S., Guttadauria, M., Erickson, J., Kim, D. D., & Dunayevich, E. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60888-4 · Cited by 1,036
Davidson, M. H., Hauptman, J., DiGirolamo, M., Foreyt, J. P., Halsted, C. H., Heber, D., Heimburger, D. C., Lucas, C. P., Robbins, D. C., Chung, J., et al. (1999) · JAMA · doi:10.1001/jama.281.3.235 · Cited by 947 · cited 1×
“Orlistat blocks absorption of 25 to 30% of fat calories and is not appreciably absorbed systemically (28, 29).”
BackgroundSodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes: A Systematic Review and Meta-analysis
Vasilakou, D., Karagiannis, T., Athanasiadou, E., Mainou, M., Liakos, A., Bekiari, E., Sarigianni, M., Matthews, D. R., & Tsapas, A. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-4-201308200-00007 · Cited by 911
Multicenter, placebo-controlled trial of lorcaserin for weight management.
Smith, S. R., Weissman, N. J., Anderson, C. M., Sanchez, M., Chuang, E., Stubbe, S., Bays, H., & Shanahan, W. R. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909809 · Cited by 911 · cited 8×
“In clinical trials, lorcaserin 10 mg QD produced nearly as much weight loss as 10 mg BID (42, 44, 45).”
BackgroundInfluentialLong-term Drug Treatment for Obesity: A Systematic and Clinical Review
Yanovski, S. Z., & Yanovski, J. A. (2014) · JAMA · doi:10.1001/jama.2013.281361 · Cited by 876 · cited 1×
“Whatever baseline behavioral treatment is given, the effect of the drug will be static (33, 34).”
BackgroundBolinder, J., Ljunggren, Ö., Kullberg, J., Johansson, L., Wilding, J., Langkilde, A. M., Sugg, J., & Parikh, S. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2260 · Cited by 867 · cited 1×
“Hence, prioritizing metformin, incretin-based medications, and SGLT-2s as therapeutic strategies can reduce exercise-related hypoglycemia and potentially increase the safety and efficacy of exercise in patients with diabetes, thus supporting this important weight-reduction strategy (67, 68).”
Backgroundon behalf of the NN8022-1923 Investigators, Wadden, T. A., Hollander, P., Klein, S., Niswender, K., Woo, V, Hale, P. M., & Aronne, L. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.120 · Cited by 842
Self-citationLong term pharmacotherapy for obesity and overweight: updated meta-analysis
Rucker, D., Padwal, R., Li, S. K., Curioni, C., & Lau, D. C. W. (2007) · BMJ · doi:10.1136/bmj.39385.413113.25 · Cited by 801
Obesity and addiction: Neurobiological overlaps
Volkow, N. D., Wang, G. ‐., Tomasi, D., & Baler, R. D. (2013) · Obesity Reviews · doi:10.1111/j.1467-789x.2012.01031.x · Cited by 800
Randomized Trial of Lifestyle Modification and Pharmacotherapy for Obesity
Wadden, T. A., Berkowitz, R. I., Womble, L. G., Sarwer, D. B., Phelan, S., Cato, R. K., Hesson, L. A., Osei, S. Y., Kaplan, R., & Stunkard, A. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050156 · Cited by 794
Sjöström, L., Gummesson, A., Sjöström, C. D., Narbro, K., Peltonen, M., Wedel, H., Bengtsson, C., Bouchard, C., Carlsson, B., Dahlgren, S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70159-7 · Cited by 770 · cited 1×
“T2DM Yes Cohen, 2012 (132); Mingrone, 2012 (133); Schauer, 2012 (134); Buchwald, 2009 (135) Hypertension Yes Ilane-Parikka, 2008 (136); Phelan, 2007 (137); Zanella, 2006 (138) Dyslipidemia and metabolic syndrome Yes Ilane-Parikka, 2008 (136); Phelan, 2007 (137); Zanella, 2006 (138) Cardiovascular disease Yes Wannameth…”
on behalf of the NN8022-1807 Investigators, Astrup, A., Carraro, R., Finer, N., Harper, A., Kunesova, M., Lean, M. E. J., Niskanen, L., Rasmussen, M. F., Rissanen, A., et al. (2012) · International Journal of Obesity · doi:10.1038/ijo.2011.158 · Cited by 757 · cited 1×
“not be increased further until tolerated (31).”
Clinical and molecular genetic spectrum of congenital deficiency of the leptin receptor.
Farooqi, I. S., Wangensteen, T., Collins, S., Kimber, W., Matarese, G., Keogh, J. M., Lank, E., Bottomley, B., Lopez-Fernandez, J., Ferraz-Amaro, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa063988 · Cited by 732 · cited 1×
“It is an anorectic hormone, which exerts its effects by inhibiting neuropeptide Y/Agouti-related peptide neurons and activating pro-opiomelanocortin (POMC)/cocaine amphetamine-related transcript neurons in the arcuate nucleus, resulting in decreased food intake and increased energy expenditure, although the increase i…”
BackgroundGarvey, W. T., Ryan, D. H., Look, M., Gadde, K. M., Allison, D. B., Peterson, C. A., Schwiers, M., Day, W. W., & Bowden, C. H. (2012) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.111.024927 · Cited by 716
Self-citationAllison, D. B., Gadde, K. M., Garvey, W. T., Peterson, C. A., Schwiers, M. L., Najarian, T., Tam, P. Y., Troupin, B., & Day, W. W. (2012) · Obesity · doi:10.1038/oby.2011.330 · Cited by 711 · cited 1×
“The product label recommends a gradual reduction of dose over 3–5 days because of the observation of seizures occurring when topiramate was stopped abruptly in patients with epilepsy (41, 43, 61).”
BackgroundAddition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes
Holman, R. R., Thorne, K. I., Farmer, A. J., Davies, M. J., Keenan, J. F., Paul, S., & Levy, J. C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa075392 · Cited by 710
Clozapine, Diabetes Mellitus, Weight Gain, and Lipid Abnormalities: A Five-Year Naturalistic Study
Henderson, D. C., Cagliero, E., Gray, C., Nasrallah, R. A., Hayden, D. L., Schoenfeld, D. A., & Goff, D. C. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.6.975 · Cited by 701
α-Glucosidase Inhibitors for Patients With Type 2 Diabetes
van de Laar, F. A., Lucassen, P. L., Akkermans, R. P., van de Lisdonk, E. H., Rutten, G. E., & van Weel, C. (2005) · Diabetes Care · doi:10.2337/diacare.28.1.154 · Cited by 690 · cited 1×
“-Glucosidase inhibitors such as acarbose and miglitol may be weight neutral or lead to a small change in weight (152, 153).”
BackgroundAntipsychotic-induced weight gain: a review of the literature.
Allison, D. B., & Casey, D. E. (2001) · PubMed · Cited by 669
Three-year efficacy of complex insulin regimens in type 2 diabetes
Holman, R. R., Farmer, A. J., Davies, M. J., Levy, J. C., Darbyshire, J. L., Keenan, J. F., & Paul, S. K. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905479 · Cited by 667 · cited 1×
“7 kg, detemir vs biphasic vs prandial, respectively) (93), and the weight advantage persisted during the 3-year trial (94).”
BackgroundChristensen, R., Bartels, E. M., Astrup, A., & Bliddal, H. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.065904 · Cited by 632 · cited 1×
“T2DM Yes Cohen, 2012 (132); Mingrone, 2012 (133); Schauer, 2012 (134); Buchwald, 2009 (135) Hypertension Yes Ilane-Parikka, 2008 (136); Phelan, 2007 (137); Zanella, 2006 (138) Dyslipidemia and metabolic syndrome Yes Ilane-Parikka, 2008 (136); Phelan, 2007 (137); Zanella, 2006 (138) Cardiovascular disease Yes Wannameth…”
Antidepressants and Body Weight: A Comprehensive Review and Meta-Analysis
Serretti, A., & Mandelli, L. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09r05346blu · Cited by 621 · cited 7×
“SSRIs such as fluoxetine and sertraline have been associated with weight loss during acute treatment (4–12 wk) and with weight neutrality in the maintenance ( 4 mo) phase (99).”
BackgroundInfluentialHomeostatic and hedonic signals interact in the regulation of food intake
Lutter, M., & Nestler, E. J. (2009) · The Journal of Nutrition · doi:10.3945/jn.108.097618 · Cited by 614
Landewé, R. B. M., Boers, M., Verhoeven, A. C., Westhovens, R., van de Laar, M. A. F. J., Markusse, H. M., van Denderen, J. C., Westedt, M. L., Peeters, A. J., Dijkmans, B. A. C., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10083 · Cited by 612
Therapeutic effects of restricted diet and exercise in obese patients with fatty liver
Ueno, T., Sugawara, H., Sujaku, K., Hashimoto, O., Tsuji, R., Tamaki, S., Torimura, T., Inuzuka, S., Sata, M., & Tanikawa, K. (1997) · Journal of Hepatology · doi:10.1016/s0168-8278(97)80287-5 · Cited by 609 · cited 1×
“T2DM Yes Cohen, 2012 (132); Mingrone, 2012 (133); Schauer, 2012 (134); Buchwald, 2009 (135) Hypertension Yes Ilane-Parikka, 2008 (136); Phelan, 2007 (137); Zanella, 2006 (138) Dyslipidemia and metabolic syndrome Yes Ilane-Parikka, 2008 (136); Phelan, 2007 (137); Zanella, 2006 (138) Cardiovascular disease Yes Wannameth…”
Rosenbaum, M. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25977 · Cited by 575
Fidler, M. C., Sanchez, M., Raether, B., Weissman, N. J., Smith, S. R., Shanahan, W. R., & Anderson, C. M. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1256 · Cited by 561 · cited 7×
“In clinical trials, lorcaserin 10 mg QD produced nearly as much weight loss as 10 mg BID (42, 44, 45).”
BackgroundInfluentialWadden, T. A., Foreyt, J. P., Foster, G. D., Hill, J. O., Klein, S., O'Neil, P. M., Perri, M. G., Pi‐Sunyer, F. X., Rock, C. L., Erickson, J. S., et al. (2011) · Obesity · doi:10.1038/oby.2010.147 · Cited by 558
O'Neil, P. M., Smith, S. R., Weissman, N. J., Fidler, M. C., Sanchez, M., Zhang, J., Raether, B., Anderson, C. M., & Shanahan, W. R. (2012) · Obesity · doi:10.1038/oby.2012.66 · Cited by 530
Lieberman, J. A. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.0207e04 · Cited by 520
Buse, J. B., Bergenstal, R. M., Glass, L. C., Heilmann, C. R., Lewis, M. S., Kwan, A. Y. M., Hoogwerf, B. J., & Rosenstock, J. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-2-201101180-00300 · Cited by 506 · cited 2×
“Buse et al (92) investigated the addition of exenatide or placebo to regimens of insulin glargine alone, or in combination with metformin or pioglitazone or both, in adult T2DM patients with HbA1c of 7.1 to 10.5%.”
BackgroundInfluentialBody Mass Index and Risk, Age of Onset, and Survival in Patients With Pancreatic Cancer
Li, D. (2009) · JAMA · doi:10.1001/jama.2009.886 · Cited by 469
SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects
Ferrannini, E., & Solini, A. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.243 · Cited by 458 · cited 1×
“The SGLT-2 inhibitors dapagliflozin and canagliflozin are a new class of antidiabetic drugs that reduce renal glucose reabsorption in the proximal convoluted tubule, leading to increased urinary glucose excretion (78).”
BackgroundHuang, M. A., Greenson, J. K., Chao, C., Anderson, L., Peterman, D., Jacobson, J., Emick, D., Lok, A. S., & Conjeevaram, H. S. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.41334.x · Cited by 444
Rosenbaum, M., Hirsch, J., Gallagher, D. A., & Leibel, R. L. (2008) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/88.4.906 · Cited by 444
Bariatric Surgery Versus Intensive Medical Therapy in Obese Patients With Diabetes
Schauer, P. R., Kashyap, S. R., Wolski, K., Brethauer, S. A., Kirwan, J. P., Pothier, C. E., Thomas, S., Abood, B., Nissen, S. E., & Bhatt, D. L. (2013) · Survey of Anesthesiology · doi:10.1097/sa.0b013e31827f316e · Cited by 410
Hepatic effects of dietary weight loss in morbidly obese subjects
Andersen, T., Gluud, C., Franzmann, M.-B., & Christoffersen, P. (1991) · Journal of Hepatology · doi:10.1016/0168-8278(91)90942-5 · Cited by 407 · cited 1×
“T2DM Yes Cohen, 2012 (132); Mingrone, 2012 (133); Schauer, 2012 (134); Buchwald, 2009 (135) Hypertension Yes Ilane-Parikka, 2008 (136); Phelan, 2007 (137); Zanella, 2006 (138) Dyslipidemia and metabolic syndrome Yes Ilane-Parikka, 2008 (136); Phelan, 2007 (137); Zanella, 2006 (138) Cardiovascular disease Yes Wannameth…”
LeBlanc, E. S., O'Connor, E., Whitlock, E. P., Patnode, C. D., & Kapka, T. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-7-201110040-00006 · Cited by 400
Cancer Incidence and Mortality After Gastric Bypass Surgery
Adams, T. D., Stroup, A. M., Gress, R. E., Adams, K. F., Calle, E. E., Smith, S. C., Halverson, R. C., Simper, S. C., Hopkins, P. N., & Hunt, S. C. (2009) · Obesity · doi:10.1038/oby.2008.610 · Cited by 394 · cited 1×
“T2DM Yes Cohen, 2012 (132); Mingrone, 2012 (133); Schauer, 2012 (134); Buchwald, 2009 (135) Hypertension Yes Ilane-Parikka, 2008 (136); Phelan, 2007 (137); Zanella, 2006 (138) Dyslipidemia and metabolic syndrome Yes Ilane-Parikka, 2008 (136); Phelan, 2007 (137); Zanella, 2006 (138) Cardiovascular disease Yes Wannameth…”
Treatment of Pediatric Obesity: A Systematic Review and Meta-Analysis of Randomized Trials
McGovern, L., Johnson, J. N., Paulo, R., Hettinger, A., Singhal, V., Kamath, C., Erwin, P. J., & Montori, V. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2409 · Cited by 386
Effect of weight reduction on hepatic abnormalities in overweight patients
Palmer, M., & Schaffner, F. (1990) · Gastroenterology · doi:10.1016/0016-5085(90)91169-7 · Cited by 374 · cited 1×
“T2DM Yes Cohen, 2012 (132); Mingrone, 2012 (133); Schauer, 2012 (134); Buchwald, 2009 (135) Hypertension Yes Ilane-Parikka, 2008 (136); Phelan, 2007 (137); Zanella, 2006 (138) Dyslipidemia and metabolic syndrome Yes Ilane-Parikka, 2008 (136); Phelan, 2007 (137); Zanella, 2006 (138) Cardiovascular disease Yes Wannameth…”
Hypothesis: β-Adrenergic Receptor Blockers and Weight Gain: A Systematic Analysis
Sharma, A. M., Pischon, T., Hardt, S., Kunz, I., & Luft, F. C. (2001) · Hypertension · doi:10.1161/01.hyp.37.2.250 · Cited by 338
Drugs Commonly Associated With Weight Change: A Systematic Review and Meta-analysis
Domecq, J. P., Prutsky, G., Leppin, A., Sonbol, M. B., Altayar, O., Undavalli, C., Wang, Z., Elraiyah, T., Brito, J. P., Mauck, K. F., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3421 · Cited by 334 · cited 20×
“Our Task Force adopted these cutpoints, realizing that they are arbitrary and only low-quality evidence supports associations determined by these cutpoints.”
InfluentialSelf-citationRandomised double-blind trial of prednisone versus radiotherapy in Graves' ophthalmopathy
Prummel, M. F., Berghout, A., Wiersinga, W. M., Mourits, M. P., Koornneef, L., & Blank, L. (1993) · The Lancet · doi:10.1016/0140-6736(93)92001-a · Cited by 332
TOS Obesity as a Disease Writing Group, Allison, D. B., Downey, M., Atkinson, R. L., Billington, C. J., Bray, G. A., Eckel, R. H., Finkelstein, E. A., Jensen, M. D., & Tremblay, A. (2008) · Obesity · doi:10.1038/oby.2008.231 · Cited by 321 · cited 1×
“Greater weight loss produces greater benefits, but modest (5 to 10%) weight loss, such as that produced by lifestyle modifications and medications, has been shown to produce significant improvements in many conditions (5, 6).”
BackgroundMäkimattila, S., Nikkilä, K., & Yki-Järvinen, H. (1999) · Diabetologia · doi:10.1007/s001250051172 · Cited by 314
Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus
Richter, B., Bandeira-Echtler, E., Bergerhoff, K., & Lerch, C. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006739.pub2 · Cited by 308 · cited 1×
“6%, respectively, in comparison with placebo (73).”
Hollander, P. A., Levy, P., Fineman, M. S., Maggs, D. G., Shen, L. Z., Strobel, S. A., Weyer, C., & Kolterman, O. G. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.784 · Cited by 307 · cited 1×
“4 kg) in treatment groups (89), with HbA1c reductions of 0.”
BackgroundHaddock, C., Poston, W., Dill, P., Foreyt, J., & Ericsson, M. (2002) · International Journal of Obesity · doi:10.1038/sj.ijo.0801889 · Cited by 303
Swiglo, B. A., Murad, M. H., Schünemann, H. J., Kunz, R., Vigersky, R. A., Guyatt, G. H., & Montori, V. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1907 · Cited by 302 · cited 1×
“A detailed description of the grading scheme has been published elsewhere (2).”
MethodSelf-citationEffects of gastric bypass surgery in patients with type 2 diabetes and only mild obesity
Cohen, R. V., Pinheiro, J. C., Schiavon, C. A., Salles, J. E., Wajchenberg, B. L., & Cummings, D. E. (2012) · Diabetes Care · doi:10.2337/dc11-2289 · Cited by 282 · cited 1×
“T2DM Yes Cohen, 2012 (132); Mingrone, 2012 (133); Schauer, 2012 (134); Buchwald, 2009 (135) Hypertension Yes Ilane-Parikka, 2008 (136); Phelan, 2007 (137); Zanella, 2006 (138) Dyslipidemia and metabolic syndrome Yes Ilane-Parikka, 2008 (136); Phelan, 2007 (137); Zanella, 2006 (138) Cardiovascular disease Yes Wannameth…”
Bariatric Surgery Versus Conventional Medical Therapy for Type 2 Diabetes
Mingrone, G., Panunzi, S., De Gaetano, A., Guidone, C., Iaconelli, A., Leccesi, L., Nanni, G., Pomp, A., Castagneto, M., Ghirlanda, G., et al. (2013) · Survey of Anesthesiology · doi:10.1097/01.sa.0000425546.30282.26 · Cited by 277
Aronne, L. J., Wadden, T. A., Peterson, C., Winslow, D., Odeh, S., & Gadde, K. M. (2013) · Obesity · doi:10.1002/oby.20584 · Cited by 274 · cited 2×
“termine 15 mg alone as able to induce over 7% weight loss at 6 months (26).”
BackgroundSelf-citationWannamethee, S. G., Shaper, A. G., & Walker, M. (2005) · Journal of Epidemiology and Community Health · doi:10.1136/jech.2003.015651 · Cited by 274 · cited 1×
“T2DM Yes Cohen, 2012 (132); Mingrone, 2012 (133); Schauer, 2012 (134); Buchwald, 2009 (135) Hypertension Yes Ilane-Parikka, 2008 (136); Phelan, 2007 (137); Zanella, 2006 (138) Dyslipidemia and metabolic syndrome Yes Ilane-Parikka, 2008 (136); Phelan, 2007 (137); Zanella, 2006 (138) Cardiovascular disease Yes Wannameth…”
Maayan, L., & Correll, C. U. (2011) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2011.0015 · Cited by 252
Glucagon-like peptide analogues for type 2 diabetes mellitus
Shyangdan, D. S., Royle, P., Clar, C., Sharma, P., Waugh, N., & Snaith, A. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006423.pub2 · Cited by 246 · cited 1×
“An analysis of 17 randomized placebo-controlled trials showed that all GLP-1 agonists reduced HbA1c levels by about 1% (62).”
Ziprasidone versus other atypical antipsychotics for schizophrenia
Komossa, K., Rummel-Kluge, C., Hunger, H., Schwarz, S., Bhoopathi, P. S., Kissling, W., & Leucht, S. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006627.pub2 · Cited by 240
Kuna, S. T., Reboussin, D. M., Borradaile, K. E., Sanders, M. H., Millman, R. P., Zammit, G., Newman, A. B., Wadden, T. A., Jakicic, J. M., Wing, R. R., et al. (2013) · Sleep · doi:10.5665/sleep.2618 · Cited by 231 · cited 1×
“T2DM Yes Cohen, 2012 (132); Mingrone, 2012 (133); Schauer, 2012 (134); Buchwald, 2009 (135) Hypertension Yes Ilane-Parikka, 2008 (136); Phelan, 2007 (137); Zanella, 2006 (138) Dyslipidemia and metabolic syndrome Yes Ilane-Parikka, 2008 (136); Phelan, 2007 (137); Zanella, 2006 (138) Cardiovascular disease Yes Wannameth…”
Progestin-only contraceptives: effects on weight
Lopez, L. M., Ramesh, S., Chen, M., Edelman, A., Otterness, C., Trussell, J., & Helmerhorst, F. M. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008815.pub4 · Cited by 230
Effects of metformin on weight loss: potential mechanisms
Malin, S. K., & Kashyap, S. R. (2014) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000095 · Cited by 223 · cited 2×
“first-line agent for T2DM and obesity, metformin (63).”
BackgroundIlanne-Parikka, P., Eriksson, J. G., Lindström, J., Peltonen, M., Aunola, S., Hämäläinen, H., Keinänen-Kiukaanniemi, S., Laakso, M., Valle, T. T., Lahtela, J., et al. (2008) · Diabetes Care · doi:10.2337/dc07-1117 · Cited by 218
Effectiveness of Lifestyle Interventions for Individuals With Severe Obesity and Type 2 Diabetes
Unick, J. L., Beavers, D., Jakicic, J. M., Kitabchi, A. E., Knowler, W. C., Wadden, T. A., Wing, R. R., & for the Look AHEAD Research Group (2011) · Diabetes Care · doi:10.2337/dc11-0874 · Cited by 218 · cited 1×
“Evidence Caloric restriction through diet and behavior modification has been shown to produce modest but effective weight loss for controlling comorbid medical problems such as diabetes, hypertension, and obstructive sleep apnea (39, 40) (Table 3).”
BackgroundWeight issues for people with epilepsy—A review
Ben‐Menachem, E. (2007) · Epilepsia · doi:10.1111/j.1528-1167.2007.01402.x · Cited by 206 · cited 1×
“In clinical practice, it is critical to weigh patients regularly, and AED selection should be based on each patient’s profile without sacrificing therapeutic efficacy (112).”
Backgroundvan Gool, C. H., Penninx, B. W. J. H., Kempen, G. I. J. M., Rejeski, W. J., Miller, G. D., van Eijk, J. T. M., Pahor, M., & Messier, S. P. (2005) · Arthritis Care & Research · doi:10.1002/art.20902 · Cited by 206 · cited 1×
“T2DM Yes Cohen, 2012 (132); Mingrone, 2012 (133); Schauer, 2012 (134); Buchwald, 2009 (135) Hypertension Yes Ilane-Parikka, 2008 (136); Phelan, 2007 (137); Zanella, 2006 (138) Dyslipidemia and metabolic syndrome Yes Ilane-Parikka, 2008 (136); Phelan, 2007 (137); Zanella, 2006 (138) Cardiovascular disease Yes Wannameth…”
Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes
Chapman, I., Parker, B., Doran, S., Feinle-Bisset, C., Wishart, J., Strobel, S., Wang, Y., Burns, C., Lush, C., Weyer, C., et al. (2005) · Diabetologia · doi:10.1007/s00125-005-1732-4 · Cited by 205 · cited 1×
“Pramlintide is an amylin analog that promotes weight loss by increasing satiety and decreasing food intake (65, 66).”
BackgroundTo Eat or Not to Eat — How the Gut Talks to the Brain
Korner, J., & Leibel, R. L. (2003) · New England Journal of Medicine · doi:10.1056/nejmp038114 · Cited by 203 · cited 2×
“releasing agents/reuptake inhibitors (Figure 2) (24).”
Effects of Orlistat on Fat‐Soluble Vitamins in Obese Adolescents
McDuffie, J. R., Calis, K. A., Booth, S. L., Uwaifo, G. I., & Yanovski, J. A. (2002) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.22.11.814.33627 · Cited by 202
DPP-4 inhibitors in the management of type 2 diabetes: A critical review of head-to-head trials
Scheen, A. J. (2012) · Diabetes & Metabolism · doi:10.1016/j.diabet.2011.11.001 · Cited by 200 · cited 1×
“DPP-4 inhibitors have better gastrointestinal tolerability than metformin yet are weight neutral (74, 75).”
BackgroundCombination contraceptives: effects on weight
Gallo, M. F., Lopez, L. M., Grimes, D. A., Schulz, K. F., & Helmerhorst, F. M. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003987.pub3 · Cited by 196
Antiobesity Pharmacotherapy: New Drugs and Emerging Targets
Kim, G. W., Lin, J. E., Blomain, E. S., & Waldman, S. A. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.204 · Cited by 191 · cited 1×
“Lorcaserin is a serotonin agent specifically stimulating the serotonin type 2c receptor (25).”
BackgroundAvenell, A., Brown, T. J., McGee, M. A., Campbell, M. K., Grant, A. M., Broom, J., Jung, R. T., & Smith, W. C. S. (2004) · Journal of Human Nutrition and Dietetics · doi:10.1111/j.1365-277x.2004.00530.x · Cited by 186
Differentiating antidepressants of the future: Efficacy and safety
Rosenzweig-Lipson, S., Beyer, C. E., Hughes, Z. A., Khawaja, X., Rajarao, S. J., Malberg, J. E., Rahman, Z., Ring, R. H., & Schechter, L. E. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.07.002 · Cited by 179 · cited 1×
“Paroxetine is considered to be the SSRI associated with the greatest long-term increase in body weight (100), amitriptyline is the most potent inducer of weight gain among the tricyclic antidepressants (99), and mirtazapine (a noradrenergic and specific serotoninergic antidepressant) is also associated with weight gai…”
BackgroundAronne, L., Fujioka, K., Aroda, V., Chen, K., Halseth, A., Kesty, N. C., Burns, C., Lush, C. W., & Weyer, C. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2003 · Cited by 178 · cited 1×
“Other studies have found more substantial weight loss of over 3 kg with the use of pramlintide (90).”
BackgroundSelf-citationRandomized, Double-Blind, Placebo-Controlled Trial of Orlistat for Weight Loss in Adolescents
Maahs, D., de Serna, D. G., Kolotkin, R. L., Ralston, S., Sandate, J., Qualls, C., & Schade, D. S. (2006) · Endocrine Practice · doi:10.4158/ep.12.1.18 · Cited by 177
Goldsmith, R., Joanisse, D. R., Gallagher, D., Pavlovich, K., Shamoon, E., Leibel, R. L., & Rosenbaum, M. (2010) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00053.2009 · Cited by 171
Simpson, G. M., Glick, I. D., Weiden, P. J., Romano, S. J., & Siu, C. O. (2004) · American Journal of Psychiatry · doi:10.1176/ajp.161.10.1837 · Cited by 170
Nathan, D. M., & for the ADA/EASD Consensus Committee (2009) · Diabetes Care · doi:10.2337/dc08-2195 · Cited by 169 · cited 1×
“Evidence Insulin remains the most effective agent to control serum glucose (81).”
BackgroundThe clinical implications of weight gain in schizophrenia.
Kurzthaler, I., & Fleischhacker, W. W. (2001) · PubMed · Cited by 166
Verrotti, A., D'Egidio, C., Mohn, A., Coppola, G., & Chiarelli, F. (2011) · Obesity Reviews · doi:10.1111/j.1467-789x.2010.00800.x · Cited by 160 · cited 1×
“Valproic acid has been shown to cause weight gain in both adults and children (113).”
BackgroundBodyweight Gain and Anticonvulsants: A Comparative Review
Jallon, P., & Picard, F. (2001) · Drug Safety · doi:10.2165/00002018-200124130-00004 · Cited by 159
Horton, E. S., Silberman, C., Davis, K. L., & Berria, R. (2010) · Diabetes Care · doi:10.2337/dc09-2062 · Cited by 156
McIntosh, B., Cameron, C. G., Singh, S. R., Yu, C., Ahuja, T. K., Welton, N. J., & Dahl, M. (2011) · PubMed Central · Cited by 155
Lee, A., Patrick, P., Wishart, J., Horowitz, M., & Morley, J. E. (2002) · Diabetes, Obesity and Metabolism · doi:10.1046/j.1463-1326.2002.00219.x · Cited by 150 · cited 1×
“-Glucosidase inhibitors such as acarbose and miglitol may be weight neutral or lead to a small change in weight (152, 153).”
BackgroundMolecular Mechanisms of Appetite Regulation
Yu, J. H., & Kim, M.-S. (2012) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2012.36.6.391 · Cited by 148
Molecular pathophysiology of metabolic effects of antipsychotic medications
Ballon, J. S., Pajvani, U. B., Freyberg, Z., Leibel, R. L., & Lieberman, J. A. (2014) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2014.07.004 · Cited by 147 · cited 1×
“fect may be similar via weight-independent mechanisms (111).”
BackgroundBody Weight Changes with β-Blocker Use: Results from GEMINI
Messerli, F. H., Bell, D. S. H., Fonseca, V. A., Katholi, R. E., McGill, J. B., Phillips, R. A., Raskin, P., Wright, J. T., Bangalore, S., Holdbrook, F. K., et al. (2007) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.10.017 · Cited by 134 · cited 1×
“19 kg, suggesting that weight gain is not a class effect of the b-adrenergic blockers (98).”
BackgroundLong-Term Persistence of Hormonal Adaptations to Weight Loss
Sumithran, P., Prendergast, L. A., Delbridge, E., Purcell, K., Shulkes, A., Kriketos, A., & Proietto, J. (2012) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0b013e318247c6f7 · Cited by 134
Wu, D., Li, L., & Liu, C. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12174 · Cited by 130
Smith, S. R., Blundell, J. E., Burns, C., Ellero, C., Schroeder, B. E., Kesty, N. C., Chen, K. S., Halseth, A. E., Lush, C. W., & Weyer, C. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00217.2007 · Cited by 130 · cited 1×
“Pramlintide is an amylin analog that promotes weight loss by increasing satiety and decreasing food intake (65, 66).”
BackgroundChanges in Body Weight With Chronic, High-Dose Gabapentin Therapy
DeToledo, J. C., Toledo, C., DeCerce, J., & Ramsay, R. E. (1997) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199708000-00006 · Cited by 129 · cited 1×
“A study of patients taking gabapentin for 12 months or more showed that of 44 patients, 57% gained more than 5% of their baseline body weight; of these, 10 patients (23%) gained more than 10% of their baseline weight (115).”
BackgroundWeight Gain in Epileptic Patients During Treatment with Valproic Acid: a Retrospective Study
(1997) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100021879 · Cited by 126 · cited 1×
“A retrospective study of long-term weight gain in adult epileptic patients on valproic acid mono- or polytherapy showed that mild-tomoderate weight gain (5 to 10% of baseline weight) was shown in 24% of patients, whereas marked weight gain ( 10% gain of baseline weight) was shown in 47% of patients (114).”
BackgroundImpact of weight loss on the metabolic syndrome
Phelan, S., Wadden, T. A., Berkowitz, R. I., Sarwer, D. B., Womble, L. G., Cato, R. K., & Rothman, R. A. (2007) · International Journal of Obesity · doi:10.1038/sj.ijo.0803606 · Cited by 123 · cited 1×
“T2DM Yes Cohen, 2012 (132); Mingrone, 2012 (133); Schauer, 2012 (134); Buchwald, 2009 (135) Hypertension Yes Ilane-Parikka, 2008 (136); Phelan, 2007 (137); Zanella, 2006 (138) Dyslipidemia and metabolic syndrome Yes Ilane-Parikka, 2008 (136); Phelan, 2007 (137); Zanella, 2006 (138) Cardiovascular disease Yes Wannameth…”
Molecular physiology of weight regulation in mice and humans
Leibel, R. L. (2008) · International Journal of Obesity · doi:10.1038/ijo.2008.245 · Cited by 120
Chow, C.-C., Tsang, L. W. W., Sorensen, J. P., & Cockram, C. S. (1995) · Diabetes Care · doi:10.2337/diacare.18.3.307 · Cited by 109
Huang, M.-H., Chen, C.-H., Chen, T.-W., Weng, M.-C., Wang, W.-T., & Wang, Y.-L. (2000) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200012)13:6<398::aid-art10>3.0.co;2-e · Cited by 107 · cited 1×
“T2DM Yes Cohen, 2012 (132); Mingrone, 2012 (133); Schauer, 2012 (134); Buchwald, 2009 (135) Hypertension Yes Ilane-Parikka, 2008 (136); Phelan, 2007 (137); Zanella, 2006 (138) Dyslipidemia and metabolic syndrome Yes Ilane-Parikka, 2008 (136); Phelan, 2007 (137); Zanella, 2006 (138) Cardiovascular disease Yes Wannameth…”
Common adverse effects of antiretroviral therapy for HIV disease.
Reust, C. (2011) · PubMed · Cited by 104
Goudswaard, A. N., Furlong, N. J., Valk, G. D., Stolk, R. P., & Rutten, G. E. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003418.pub2 · Cited by 103
Caton, P. W., Kieswich, J., Yaqoob, M. M., Holness, M. J., & Sugden, M. C. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01466.x · Cited by 101 · cited 1×
“However, in animal models, metformin mediates a phenotypic shift away from lipid accretion through AMP-activated Protein Kinase-Nicotinamide phosphoribosyltransferase-Sirtuin 1-mediated changes in metabolism supporting treatment for obesity (64).”
BackgroundDoes insulin detemir have a role in reducing risk of insulin‐associated weight gain?
Hermansen, K., & Davies, M. (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00665.x · Cited by 100
Tolerability and safety aspects of mirtazapine
Nutt, D. J. (2002) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.388 · Cited by 92 · cited 1×
“Paroxetine is considered to be the SSRI associated with the greatest long-term increase in body weight (100), amitriptyline is the most potent inducer of weight gain among the tricyclic antidepressants (99), and mirtazapine (a noradrenergic and specific serotoninergic antidepressant) is also associated with weight gai…”
BackgroundRatliff, J. C., Barber, J. A., Palmese, L. B., Reutenauer, E. L., & Tek, C. (2010) · Obesity · doi:10.1038/oby.2010.176 · Cited by 86 · cited 2×
“A recent study demonstrated that the odds ratio for being overweight was increased in prescription H1 antihistamine users (129).”
BackgroundMethodInfluence of Knee Osteoarthritis on Exercise Capacity and Quality of Life in Obese Adults
Sütbeyaz, S. T., Sezer, N., Köseoğlu, B. F., Ibrahimoğlu, F., & Tekin, D. (2007) · Obesity · doi:10.1038/oby.2007.246 · Cited by 81 · cited 1×
“This is particularly important in rheumatic diseases because, for example, obesity in the setting of osteoarthritis leads to more severe disability and reduced exercise capacity, ambulatory capacity, and quality of life (122).”
BackgroundHinkle, W., Cordell, M., Leibel, R., Rosenbaum, M., & Hirsch, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059114 · Cited by 79
Singh‐Franco, D., Perez, A., & Harrington, C. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01337.x · Cited by 76 · cited 1×
“57 kg for those taking pramlintide vs the control groups (77).”
BackgroundBupropion and Bupropion Analogs as Treatments for CNS Disorders
Carroll, F. I., Blough, B. E., Mascarella, S. W., Navarro, H. A., Lukas, R. J., & Damaj, M. I. (2014) · Advances in pharmacology · doi:10.1016/b978-0-12-420118-7.00005-6 · Cited by 75 · cited 1×
“Bupropion is a dopamine and norepinephrine reuptake inhibitor (27), which stimulates POMC neurons.”
BackgroundWeight gain in type 2 diabetes mellitus
Jacob, A. N., Salinas, K., Adams‐Huet, B., & Raskin, P. (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00622.x · Cited by 75
Long-term weight control study II (weeks 34 to 104)
Weintraub, M., Sundaresan, P. R., Schuster, B., Ginsberg, G., Madan, M., Balder, A., Stein, E. C., & Byrne, L. (1992) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1992.70 · Cited by 72
lov, K. R., Tamer, S. C., Clauson, P., & Karl, D. M. (2007) · Clinical Drug Investigation · doi:10.2165/00044011-200727040-00007 · Cited by 70
Effect of exercise training on long-term weight maintenance in weight-reduced men
Pasman, W. J., Saris, W. H. M., Muls, E., Vansant, G. A. A. M., & Westerterp‐Plantenga, M. S. (1999) · Metabolism · doi:10.1016/s0026-0495(99)90004-5 · Cited by 69
Addiction potential of phentermine prescribed during long-term treatment of obesity
Hendricks, E. J., Srisurapanont, M., Schmidt, S. L., Haggard, M., Souter, S., Mitchell, C. L., De Marco, D. G., Hendricks, M. J., Istratiy, Y., & Greenway, F. L. (2014) · International Journal of Obesity · doi:10.1038/ijo.2013.74 · Cited by 67 · cited 1×
“There currently are no long-term data on safety or efficacy, although recent data on 269 patients treated long term with phentermine suggest that the addiction potential is low (131).”
BackgroundBupropion for weight reduction
Gadde, K. M., & Xiong, G. L. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.1.17 · Cited by 64 · cited 2×
“It is the only antidepressant that consistently causes weight loss (103).”
BackgroundHollander, P. A., Rašlová, K., Skjøth, T. V., Råstam, J., & Liutkus, J. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01351.x · Cited by 61 · cited 1×
“Other weight-sparing regimens have been studied, including the combination of basal insulin with the weightneutral DPP-4 inhibitor sitagliptin (91) and weight-reducing combination therapy with liraglutide and metformin.”
BackgroundAnderson, J. W., Schwartz, S. M., Hauptman, J., Boldrin, M., Rossi, M., Bansal, V., & Hale, C. A. (2006) · Annals of Pharmacotherapy · doi:10.1345/aph.1h234 · Cited by 51
Wainstein, J., Katz, L., Engel, S. S., Xu, L., Golm, G. T., Hussain, S., O’Neill, E. A., Kaufman, K. D., & Goldstein, B. J. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01530.x · Cited by 48
Grandy, S., Hashemi, M., Langkilde, A. ‐., Parikh, S., & Sjöström, C. D. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12263 · Cited by 44 · cited 1×
“Hence, prioritizing metformin, incretin-based medications, and SGLT-2s as therapeutic strategies can reduce exercise-related hypoglycemia and potentially increase the safety and efficacy of exercise in patients with diabetes, thus supporting this important weight-reduction strategy (67, 68).”
BackgroundA review of biobehavioral research in juvenile primary fibromyalgia syndrome
Kashikar‐Zuck, S., Graham, T. B., Huenefeld, M. D., & Powers, S. W. (2000) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200012)13:6<388::aid-art9>3.0.co;2-p · Cited by 41
Fanghänel, G., Cortinas, L., Sánchez‐Reyes, L., & Berber, A. C. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801592 · Cited by 38
Gastrointestinal peptides controlling body weight homeostasis
Zerón, H. M., López, M., & Diéguez, C. (2007) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2007.11.009 · Cited by 36
Modification in body weight associated with antiepileptic drugs
de Gaspari, C. N., & Guerreiro, C. A. M. (2010) · Arquivos de Neuro-Psiquiatria · doi:10.1590/s0004-282x2010000200024 · Cited by 35 · cited 1×
“5 kg at a 6- to 8-month follow-up visit (117).”
BackgroundNebivolol in Obese and Non‐Obese Hypertensive Patients
Manrique, C. M., Whaley‐Connell, A. T., & Sowers, J. R. (2009) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2009.00119.x · Cited by 29 · cited 1×
“If required, selective or nonselective -blockers with a vasodilating component such as carvedilol and nebivolol are recommended because these agents appear to have less weight gain potential and less of an impact on glucose and lipid metabolism than other nonselective -blockers (96, 97).”
BackgroundRevisiting the Toxicity of Low‐Dose Glucocorticoids: Risks and Fears
da Silva, J. A. P., Jacobs, J. W. G., & Bijlsma, J. W. J. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1351.026 · Cited by 28 · cited 1×
“A systematic review reported that, based on data from four RCTs in rheumatoid arthritis, glucocorticoids cause a weight increase of 4 to 8% (123, 124).”
BackgroundWeight gain associated with protease inhibitor therapy in HIV-infected patients
Stricker, R. B., & Goldberg, B. (1998) · Research in Virology · doi:10.1016/s0923-2516(98)80088-5 · Cited by 25 · cited 1×
“deposition of visceral adipose tissue (120) and lipodystro-”
BackgroundZanella, M. T., Uehara, M. H., Ribeiro, A. B., Bertolami, M. C., Falsetti, A. C., & Yunes, M. A. (2006) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302006000200023 · Cited by 22 · cited 1×
“T2DM Yes Cohen, 2012 (132); Mingrone, 2012 (133); Schauer, 2012 (134); Buchwald, 2009 (135) Hypertension Yes Ilane-Parikka, 2008 (136); Phelan, 2007 (137); Zanella, 2006 (138) Dyslipidemia and metabolic syndrome Yes Ilane-Parikka, 2008 (136); Phelan, 2007 (137); Zanella, 2006 (138) Cardiovascular disease Yes Wannameth…”
Weber, E., STACK, J. A., Pollock, B. G., Mulsant, B. H., Begley, A. E., Mazumdar, S., & Reynolds, C. F. (2000) · American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200008000-00011 · Cited by 22 · cited 1×
“Other specific tricyclics that have been associated with weight gain include nortriptyline (102), whereas the effect of imipramine seems to be neutral (99).”
BackgroundFransen, M. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20257 · Cited by 20 · cited 2×
“T2DM Yes Cohen, 2012 (132); Mingrone, 2012 (133); Schauer, 2012 (134); Buchwald, 2009 (135) Hypertension Yes Ilane-Parikka, 2008 (136); Phelan, 2007 (137); Zanella, 2006 (138) Dyslipidemia and metabolic syndrome Yes Ilane-Parikka, 2008 (136); Phelan, 2007 (137); Zanella, 2006 (138) Cardiovascular disease Yes Wannameth…”
McDonnell, M. E. (2007) · Journal of Cardiopulmonary Rehabilitation and Prevention · doi:10.1097/01.hcr.0000281762.29287.a6 · Cited by 17 · cited 1×
“Exercise adjustment is generally necessary only with insulin and with medications that can promote endogenous insulin secretion despite decreasing glucose levels, such as the sulfonylurea and glinide classes of agents (80).”
BackgroundSelf-citationPrevention or Retardation of Joint Damage in Rheumatoid Arthritis
Boers, M., & van der Heijde, D. (2002) · Drugs · doi:10.2165/00003495-200262120-00002 · Cited by 10 · cited 1×
“7-kg weight gain after 1 year of treatment (125, 126), and another showed a 2.”
BackgroundJacobs, J. W. G., Boers, M., Kirwan, J., & Bijlsma, J. W. J. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22049 · Cited by 6
Modification in body weight associated with antiepileptic drugs
de Gaspari, C. N., & Guerreiro, C. A. M. (2010) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) · Cited by 6
Benefits of Lifestyle Modification in the Pharmacologic Treatment of Obesity: A Randomized Trial
Wadden, T. A., Berkowitz, R. I., Sarwer, D. B., Prus-Wisniewski, R., & Steinberg, C. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.2.218 · Cited by 1 · cited 2×
“Whatever baseline behavioral treatment is given, the effect of the drug will be static (33, 34).”
Background
Research works printed but not linked: 15
- [3]3. DomecqJP,PrutskyG,LeppinA,etal. Drugscommonlyassociated with weight change: a systematic review and meta-analysis. J Clin Endocrinol Metab . 2015;100:363-370.
- [11]11. Goldsmith R, Joanisse DR, Gallagher D, et al. Effects of experimentalweightperturbationonskeletalmuscleworkefficiency,fuel utilization, and biochemistry in human subjects. Am J Physiol Regul Integr Comp Physiol . 2010;298:R79-R88.
- [19]19. Stahl SM. Impulsivity, compulsivity, and addiction. In: Stahl's Essential Psychopharmacology . 4th ed. New York, NY: Cambridge University Press; 2013:537-575.
- [22]22. Mendieta-ZerónH,LópezM,DiéguezC. Gastrointestinalpeptides controlling body weight homeostasis. Gen Comp Endocrinol . 2008;155:481-495.
- [35]35. Avenell A, Brown TJ, McGee MA, et al. Whatinterventions should weaddtoweightreducingdietsinadultswithobesity?Asystematic review of randomized controlled trials of adding drug therapy, exercise, behaviourtherapyorcombinationsoftheseinterventions. J Hum Nutr Diet . 2004;17:293-316.
- [68]68. Grandy S, Hashemi M, Langkilde AM, Parikh S, Sjöström CD. Changesinweightloss-related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin. Diabetes Obes Metab . 2014;16:645-650.
- [79]79. Greenway FL, Fujioka K, Plodkonski RA, et al. COR I Study Group. Lancet . 2010;376:595-605.
- [82]82. Jacob AN, Salinas K, Adams-Huet B, Raskin P. Weightgainintype 2 diabetes mellitus. Diabetes Obes Metab . 2007;9:386-393.
- [88]88. Mäkimattila S, Nikkilä K, Yki-Järvinen H. Causes of weight gain duringinsulintherapywithandwithoutmetformininpatientswith type II diabetes mellitus. Diabetologia . 1999;42:406-412.
- [95]95. WingLM,ReidCM,RyanP,etal. Acomparisonofoutcomeswith angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med . 2003;348:583-592.
- [110]110. MaayanL,CorrellCU. Weightgainandmetabolicrisks associated withantipsychoticmedicationsinchildrenandadolescents. J Child Adolesc Psychopharmacol . 2011;21:517-535.
- [126]126. Boers M, van der Heijde DM. Prevention or retardation of joint damageinrheumatoidarthritis:issuesofdefinition,evaluationand interpretation of plain radiographs. Drugs . 2002;62(12):17171724.
- [128]128. Aronne LJ. Drug-induced weight gain: non-CNS medications. In: Aronne LJ, ed. A Practical Guide to Drug-Induced Weight Gain . Minneapolis, MN: McGraw-Hill; 2002:77-91.
- [14]14. tional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J Gastroenterol . 2005;100:1072-1081.
- [146]146. Huang MH, Chen CH, Chen TW, Weng MC, Wang WT, Wang YL. Theeffectsofweightreductionontherehabilitationofpatients with knee osteoarthritis and obesity. Arthritis Care Res . 2000;13: 398-405.
Cited by
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Self-citationDavies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
European Guidelines for Obesity Management in Adults
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Mechanisms, Pathophysiology, and Management of Obesity
Heymsfield, S. B., & Wadden, T. A. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1514009 · Cited by 1,867
Metadata
- Authors
- Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D.
- Affiliations
- Pennington Biomedical Research Center (US)
- Cornell University (US)
- Denver Health Medical Center (US)
- Brigham and Women's Hospital (US)
- Mayo Clinic (US)
- IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola (IT)
- Geisinger Health System (US)
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2015-02
- Volume
- 100
- Issue
- 2
- Pages
- 342-362
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2109366467
- Semantic Scholar
- 32e063efbad03793d5b9794138fe9a8f9b3a4650
- Cited by
- 1,347
- References
- 154
- Citations by year
- 2026: 109 · 2025: 128 · 2024: 157 · 2023: 134 · 2022: 112 · 2021: 129 · 2020: 132 · 2019: 98 · 2018: 91 · 2017: 102 · 2016: 95 · 2015: 55
- FWCI
- 82.37
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, cc-by-nc-nd)
- INFM-OAR (INFN Catania) (submittedVersion, other-oa)
- Zenodo (CERN European Organization for Nuclear Research) (cc-by)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
- Keywords
- obesity, anti-obesity drugs, weight loss, lifestyle modification, obesity-related comorbidities, medication-induced weight gain, drug prescribing, chronic disease medications
- MeSH terms
- Endocrinology, Humans, Obesity, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.